Segall Bryant & Hamill LLC Has $5.03 Million Position in Haemonetics Co. (NYSE:HAE)

Segall Bryant & Hamill LLC grew its position in shares of Haemonetics Co. (NYSE:HAE) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,621 shares of the medical instruments supplier’s stock after purchasing an additional 407 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.12% of Haemonetics worth $5,033,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in HAE. Thrivent Financial for Lutherans boosted its position in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after buying an additional 250,833 shares during the period. Royce & Associates LP raised its stake in shares of Haemonetics by 2.6% during the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after acquiring an additional 30,868 shares during the last quarter. Zions Bancorporation N.A. lifted its holdings in shares of Haemonetics by 19.5% during the third quarter. Zions Bancorporation N.A. now owns 26,234 shares of the medical instruments supplier’s stock worth $2,109,000 after purchasing an additional 4,278 shares during the period. Victory Capital Management Inc. grew its stake in shares of Haemonetics by 0.6% in the third quarter. Victory Capital Management Inc. now owns 278,886 shares of the medical instruments supplier’s stock worth $22,417,000 after purchasing an additional 1,717 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new stake in Haemonetics in the third quarter valued at $479,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

NYSE:HAE opened at $85.51 on Friday. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The business has a fifty day simple moving average of $78.75 and a two-hundred day simple moving average of $82.49. The company has a market capitalization of $4.29 billion, a P/E ratio of 35.48, a P/E/G ratio of 1.32 and a beta of 0.32.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same quarter in the previous year, the firm earned $0.99 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price target on the stock. Barrington Research reiterated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a report on Friday, November 8th. BTIG Research initiated coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Finally, Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $107.88.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.